The Journal of Pain
Volume 10, Issue 11 , Pages 1146-1150 , November 2009

Chemotherapy-Induced Peripheral Neuropathy as a Predictor of Neuropathic Pain in Breast Cancer Patients Previously Treated With Paclitaxel

  • Cielito C. Reyes-Gibby

      Affiliations

    • Department of Epidemiology, Division of Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    • Corresponding Author InformationAddress reprint requests to Dr. Cielito C. Reyes-Gibby, DrPH, Department of Epidemiology, Unit #1340, The University of Texas M. D. Anderson Cancer Center, 1155 Pressler Drive, Houston, TX 77030.
    • ,
  • Phuong Khang Morrow

      Affiliations

    • Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Aman Buzdar

      Affiliations

    • Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
    • ,
  • Sanjay Shete

      Affiliations

    • Department of Epidemiology, Division of Cancer Prevention, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA

Received 26 January 2009 ,Revised 8 April 2009 ,Accepted 14 April 2009.

References 

  1. Attal N, Cruccu G, Haanpaa M, Hansson P, Jensen TS, Nurmikko T, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13:1153–1169
  2. Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, et al. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: Preliminary data of a prospective randomized trial. Clin Cancer Res. 2002;8:1073–1079
  3. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain. 1999;82:263–274
  4. Cherny NI. Opioid analgesics: Comparative features and prescribing guidelines. Drugs. 1996;51:713–737
  5. Cherny NI, Thaler HT, Friedlander-Klar H, Lapin J, Foley KM, Houde R, et al. Opioid responsiveness of cancer pain syndromes caused by neuropathic or nociceptive mechanisms: A combined analysis of controlled, single-dose studies. Neurology. 1994;44:857–861
  6. Dennis SG, Melzack R. Self-mutilation after dorsal rhizotomy in rats: Effects of prior pain and pattern of root lesions. Exp Neurol. 1979;65:412–421
  7. Dray A, Read SJ. Arthritis and pain. Future targets to control osteoarthritis pain. Arthritis Res Ther. 2007;9:212
  8. Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel- and vincristine-induced painful peripheral neuropathy. Pain. 2004;109:150–161
  9. Flatters SJ, Bennett GJ. Studies of peripheral sensory nerves in paclitaxel-induced painful peripheral neuropathy: Evidence for mitochondrial dysfunction. Pain. 2006;122:245–257
  10. Flatters SJ, Fox AJ, Dickenson AH. Spinal interleukin-6 (IL-6) inhibits nociceptive transmission following neuropathy. Brain Res. 2003;984:54–62
  11. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF, et al. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005;23:5983–5992
  12. Grond S, Radbruch L, Meuser T, Sabatowski R, Loick G, Lehmann KA. Assessment and treatment of neuropathic cancer pain following WHO guidelines. Pain. 1999;79:15–20
  13. Ivanavicius SP, Ball AD, Heapy CG, Westwood FR, Murray F, Read SJ. Structural pathology in a rodent model of osteoarthritis is associated with neuropathic pain: Increased expression of ATF-3 and pharmacological characterisation. Pain. 2007;128:272–282
  14. Jacobson SD, Loprinzi CL, Sloan JA, Wilke JL, Novotny PJ, Okuno SH, et al. Glutamine does not prevent paclitaxel-associated myalgias and arthralgias. J Support Oncol. 2003;1:274–278
  15. Jin HW, Flatters SJ, Xiao WH, Mulhern HL, Bennett GJ. Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: Effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. Exp Neurol. 2008;210:229–237
  16. Kannarkat G, Lasher EE, Schiff D. Neurologic complications of chemotherapy agents. Curr Opin Neurol. 2007;20:719–725
  17. Moulin DE, Clark AJ, Gilron I, Ware MA, Watson CP, Sessle BJ, et al. Pharmacological management of chronic neuropathic pain-consensus statement and guidelines from the Canadian Pain Society. Pain Res Manag. 2007;12:13–21
  18. Naguib M, Diaz P, Xu JJ, struc-Diaz F, Craig S, Vivas-Mejia P, et al. MDA7: A novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models. Br J Pharmacol. 2008;155:1104–1116
  19. Nail LM. Long-term persistence of symptoms. Semin Oncol Nurs. 2001;17:249–254
  20. Ong EC. Controlled-release oxycodone in the treatment of neuropathic pain of nonmalignant and malignant causes. Oncology. 2008;74(Suppl 1):72–75
  21. Paice JA. Mechanisms and management of neuropathic pain in cancer. J Support Oncol. 2003;1:107–120
  22. Park SB, Krishnan AV, Lin CS, Goldstein D, Friedlander M, Kiernan MC. Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem. 2008;15:3081–3094
  23. Quasthoff S, Hartung HP. Chemotherapy-induced peripheral neuropathy. J Neurol. 2002;249:9–17
  24. Rabin AG, Anderson EG. Autotomy following limb denervation: Effects of previous exposure to neurectomy. Pain. 1985;21:105–115
  25. Rao RD, Michalak JC, Sloan JA, Loprinzi CL, Soori GS, Nikcevich DA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: A phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007;110:2110–2118
  26. Read SJ, Dray A. Osteoarthritic pain: A review of current, theoretical and emerging therapeutics. Expert Opin Investig Drugs. 2008;17:619–640
  27. Scripture CD, Figg WD, Sparreboom A. Peripheral neuropathy induced by Paclitaxel: Recent insights and future perspectives. Curr Neuropharmacol. 2006;4:165–172
  28. Tsavaris N, Kopterides P, Kosmas C, Efthymiou A, Skopelitis H, Dimitrakopoulos A, et al. Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: A pilot study. Pain Med. 2008;9:1209–1216
  29. Verstappen CC, Heimans JJ, Hoekman K, Postma TJ. Neurotoxic complications of chemotherapy in patients with cancer: Clinical signs and optimal management. Drugs. 2003;63:1549–1563
  30. Vigano A, Bruera E, Suarez-Almazor ME. Age, pain intensity, and opioid dose in patients with advanced cancer. Cancer. 1998;83:1244–1250
  31. Visovsky C, Meyer RR, Roller J, Poppas M. Evaluation and management of peripheral neuropathy in diabetic patients with cancer. Clin J Oncol Nurs. 2008;12:243–247
  32. Wampler MA, Hamolsky D, Hamel K, Melisko M, Topp KS. Case report: Painful peripheral neuropathy following treatment with docetaxel for breast cancer. Clin J Oncol Nurs. 2005;9:189–193
  33. Wolf S, Barton D, Kottschade L, Grothey A, Loprinzi C. Chemotherapy-induced peripheral neuropathy: Prevention and treatment strategies. Eur J Cancer. 2008;44:1507–1515
  34. Xiao W, Naso L, Bennett GJ. Experimental studies of potential analgesics for the treatment of chemotherapy-evoked painful peripheral neuropathies. Pain Med. 2008;9:505–517
  35. Zeltser R, Beilin B, Zaslansky R, Seltzer Z. Comparison of autotomy behavior induced in rats by various clinically-used neurectomy methods. Pain. 2000;89:19–24

 GRANT SUPPORTED BY THE NATIONAL CANCER INSTITUTE (CA109043) and Pfizer, Inc.

PII: S1526-5900(09)00497-0

doi: 10.1016/j.jpain.2009.04.006

The Journal of Pain
Volume 10, Issue 11 , Pages 1146-1150 , November 2009

Article Tools